Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs
21 août 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
31 juil. 2019 08h00 HE
|
Pluristem Therapeutics, Inc.
PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineagesData is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop HAIFA,...
Pluristem Therapeutics’ CEO Issues Shareholders Update
24 juil. 2019 10h45 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Announces One-for-Ten Reverse Split of its Common Shares
24 juil. 2019 02h45 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
17 juil. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
Data will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network (RITN) Workshop on July 31st HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
Pluristem Therapeutics’ CEO Issues Shareholder Letter
02 juil. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 02, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board
24 juin 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, June 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product
17 juin 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Lead Physicians in Pluristem’s Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper
15 mai 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry
06 mai 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...